Sol-Gel Technologies Announces Last Patient Last Visit In Pivotal Phase 3 Trial Of SGT-610 For Gorlin Syndrome; Says Top-Line Results On Track For Late November

Loading news article.

Sol-Gel Technologies Announces Last Patient Last Visit In Pivotal Phase 3 Trial Of SGT-610 For Gorlin Syndrome; Says Top-Line Results On Track For Late November | WAPE

Sol-Gel Technologies Announces Last Patient Last Visit In Pivotal Phase 3 Trial Of SGT-610 For Gorlin Syndrome; Says Top-Line Results On Track For Late November

Article summary

Related companies

Comments —